NRX Pharmaceuticals
NRXP
31 hedge funds and large institutions have $1.76M invested in NRX Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 3 closing their positions.
720% more call options, than puts
Call options by funds: $41K | Put options by funds: $5K
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
3% more funds holding
Funds holding: 30 → 31 (+1)
0.07% less ownership
Funds ownership: 0.47% → 0.4% (-0.07%)
5% less capital invested
Capital invested by funds: $1.86M → $1.76M (-$97.1K)
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$18.2K |
| 2 |
Jane Street
New York
|
+$12.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$797 |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$92 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$69.2K |
| 2 |
HAG
HighPoint Advisor Group
Downers Grove,
Illinois
|
-$23K |
| 3 |
Morgan Stanley
New York
|
-$20.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$13.9K |
| 5 |
HSA
HBK Sorce Advisory
Erie,
Pennsylvania
|
-$13.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $232 | -$7.52K | -1,632 | -97% |
|
|
LFG
27
Larson Financial Group
St Louis,
Missouri
| $103 | – | – | – |
|
28
Qube Research & Technologies (QRT)
London,
United Kingdom
| $78 | – | – | – |
|
29
Fidelity Investments
Boston,
Massachusetts
| $52 | +$51 | +11 | New |
|
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$69.2K | -15,008 | -100% |
|
|
HAG
31
HighPoint Advisor Group
Downers Grove,
Illinois
| – | -$23K | -4,350 | Closed |
|
|
HSA
32
HBK Sorce Advisory
Erie,
Pennsylvania
| – | -$13.4K | -2,923 | Closed |
|
33
Bank of America
Charlotte,
North Carolina
| – | -$34 | -7 | Closed |
|
|
34
Simplex Trading
Chicago,
Illinois
| – | +$92 | +20 | New |
|
NRXP Hedge Fund Activity: Q1 2024 in Review
31 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q1 2024, worth a combined $1.76M — down 5.2% from $1.86M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NRXP positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 9 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $18.2K. The largest seller was Royal Bank of Canada, cutting an estimated $69.2K.
- 31 institutional investors held NRX Pharmaceuticals (NRXP) as of Q1 2024, up from 30 in Q4 2023.
- Funds reported $1.76M of NRX Pharmaceuticals stock for Q1 2024, down 5.2% quarter-over-quarter.
- 4 funds opened new NRX Pharmaceuticals positions in Q1 2024 and 3 closed out, a net change of +1 holder.
- The largest NRX Pharmaceuticals buyer in Q1 2024 was XTX Topco, an estimated $18.2K added.
- The largest NRX Pharmaceuticals seller in Q1 2024 was Royal Bank of Canada, an estimated $69.2K sold.
Based on aggregated 13F filings for Q1 2024.